Regeneron Pharmaceuticals Inc. (REGN)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591

Regeneron Pharmaceuticals Inc. discovers, develops, and intends to commercialize pharmaceutical products for the treatment of medical conditions. The company focuses on three clinical development programs: VEGF Trap in oncology; VEGF Trap eye formulation in eye diseases; and IL-1 Trap in systemic inflammatory indications.

Data based on most recent fiscal year report
Market Cap35.755 Billion Shares Outstanding107.63 Million Avg Volume1.421 Million
1-Yr BETA vs S&P TR Current Ratio3.82 Quick Ratio3.18
View SEC Filings from REGN instead.
Q1 2019 All Institutions Hedge Funds 1
To trade REGN now:
Filers who had this stock in their top 10: 11 3 (0.31%)
13F Filers holding this stock: 688 71 (7.24%)
Aggregate 13F shares on 03/31/2019: 73.076 Million 7.876 Million
Aggregate 13F shares on 12/31/2018: 73.194 Million 8.835 Million
Percent change: -0.16% -10.86%
Funds creating new positions: 112 20
Funds Adding to an existing position: 290 25
Funds closing out their position: 59 10
Funds reducing their position: 186 22
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

 

Regeneron Pharmaceuticals Inc. Chart by YCharts

Yahoo! Finance

finviz

Check out our reporting and analysis

Funds Holding REGN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

10.9 Thousand total shares from 3 transactions

Exercise Derivative Conversion (M)

25.4 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GOLDSTEIN JOSEPH L

  • Director
 11,323 2019-05-15 7

POON CHRISTINE A

  • Director
 0 2019-05-14 1

STAHL NEIL EVP RESEARCH AND DEVELOPMENT

  • Officer
 44,681 2019-05-13 3

FENIMORE CHRISTOPHER R. VP CONTROLLER

  • Officer
 14,754 2019-04-18 5

SCHLEIFER LEONARD S PRESIDENT & CEO

  • Officer
  • Director
 429,848 2019-03-21 2

SANOFI

23,523,269 2019-03-08 3

BASSLER BONNIE L

  • Director
 0 2019-02-27 1

RYAN ARTHUR F

  • Director
 60,994 2019-02-14 1

BROWN MICHAEL S

  • Director
 17,672 2019-01-02 3

TESSIER-LAVIGNE MARC

  • Director
 1,510 2019-01-02 1

SING GEORGE L

  • Director
 132,595 2019-01-02 1

ZOGHBI HUDA Y

  • Director
 323 2019-01-02 1

COLES N ANTHONY

  • Director
 323 2019-01-02 1

YANCOPOULOS GEORGE PRESIDENT AND CHIEF SCIENTIFIC

  • Officer
  • Director
 1,083,358 2018-12-13 1

VAGELOS P ROY CHAIRMAN OF THE BOARD

  • Officer
  • Director
 402,036 2018-12-12 4

VAN PLEW DANIEL P EVP & GENERAL MGR INDUSTRIAL O

  • Officer
 0 2018-12-12 1

LAROSA JOSEPH J SVP GENERAL COUNSEL AND SECRET

  • Officer
 0 2018-12-12 1

LANDRY ROBERT E SVP FINANCE & CFO

  • Officer
 17,457 2018-12-12 2

MCCOURT MARION SVP COMMERCIAL

  • Officer
 12,500 2018-12-12 1

INGRAM ROBERT ALEXANDER

  • Director
 77,710 2018-10-17 0

GOLDBERG MURRAY A

  • Director
 6,300 2018-06-07 0

BAKER CHARLES A

  • Director
 0 2018-01-02 0

TERIFAY ROBERT J EVP COMMERCIAL

  • Officer
 0 2017-12-12 0

ABERMAN MICHAEL S SVP STRATEGY INVESTOR RELATION

  • Officer
 16,946 2017-06-21 0

POWCHIK PETER SVP CLINICAL DEVELOPMENT & REG

  • Officer
 32,306 2016-12-16 0

MCCORKLE DOUGLAS S VP CONTROLLER AND ASST TREASUR

  • Officer
 10,995 2015-12-29 0

GILMAN ALFRED G

  • Director
 8,912 2015-08-06 0

SHOOTER ERIC M

  • Director
 5,000 2014-02-12 0

ROBERTS WILLIAM VP REG DEV & MED SAFETY

  • Officer
 53,879 2013-09-18 0

SANOFI-AVENTIS

SANOFI-AVENTIS AMERIQUE DU NORD S.N.C.

  • 10% Owner
 15,816,953 2010-10-13 0

KOLINSKI STUART SVP GENERAL COUNSEL AND SECRET

  • Officer
 20,039 2010-06-03 0

DWORKIN PETER VP INVESTOR RELATIONS & COMMUN

  • Officer
 0 2009-12-18 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

GOLDSTEIN JOSEPH L - Director

2019-05-15 S 1,000 $305.93 d 11,323 11,323.00 direct

STAHL NEIL - Officer EVP RESEARCH AND DEVELOPMENT

2019-05-14 S 3,278 $306.37 d 22,450 44,681.00 direct

STAHL NEIL - Officer EVP RESEARCH AND DEVELOPMENT

2019-05-14 S 6,575 $305.43 d 25,728 44,681.00 direct

STAHL NEIL - Officer EVP RESEARCH AND DEVELOPMENT

2019-05-13 M 25,000 $52.03 a 47,450 44,681.00 direct

STAHL NEIL - Officer EVP RESEARCH AND DEVELOPMENT

2019-05-13 M 25,000 d 98,079 44,681.00 direct

STAHL NEIL - Officer EVP RESEARCH AND DEVELOPMENT

2019-05-13 F 15,147 $304.20 d 32,303 44,681.00 direct

FENIMORE CHRISTOPHER R. - Officer VP CONTROLLER

2019-04-18 M 350 $21.25 a 7,446 14,754.00 direct

FENIMORE CHRISTOPHER R. - Officer VP CONTROLLER by trust

2019-04-18 G 350 a 1,897 14,754.00 indirect

FENIMORE CHRISTOPHER R. - Officer VP CONTROLLER

2019-04-18 G 350 d 7,096 14,754.00 direct

FENIMORE CHRISTOPHER R. - Officer VP CONTROLLER

2019-04-18 M 350 d 0 14,754.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments